Moberg Pharma AB

MOB

SE0020353928

Pharmaceuticals

Delayed Nasdaq Stockholm Other stock markets 05:34:40 30/05/2024 pm IST			5-day change	1st Jan Change
26.24 ^SEK	+7.98%		+4.63%	+69.34%

14/05	Moberg Pharma AB Elects Jonas Ekblom as Board Member	CI
07/05	Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Peter Wolpert and Fredrik Granström Step-Down from the Board

May 10, 2022 at 11:30 am IST

The nomination committee of Moberg Pharma AB (publ) announced that Current Chairman and founder Peter Wolpert is leaving the Board but will remain one of the company's major owners. Fredrik Granström is also stepping down from the Board but will retain his role as the company's legal advisor.

Latest news about Moberg Pharma AB

Moberg Pharma AB Elects Jonas Ekblom as Board Member	14/05	CI
Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure	06/05	CI
Moberg Pharma AB Announces Launch Update for Mob-015	23/04	CI
Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	08/04	CI
Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	26/02	CI
Moberg Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/02	CI
Moberg Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	13/02	CI
Moberg Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
Moberg Pharma Announces Leadership Changes	07/11	CI
Moberg Pharma AB Appoints Nomination Committee	17/23/17	CI
Moberg Pharma Completes Patient Recruitment for North American Trial of Nail Fungus Treatment	06/23/06	MT
Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America	06/23/06	CI
Moberg Pharma to Issue New Units as Guarantors' Commission; Shares Falls 11%	08/23/08	MT
Moberg Pharma Raises SEK100 Million in Oversubscribed Rights Issue; Shares Surge 22%	01/23/01	MT
Moberg Pharma to Launch SEK100 Million Rights Offering	07/23/07	MT
Moberg Pharma Surges 39% With Swedish Approval for Fungal Nail Infection Treatment	04/23/04	MT
Moberg Pharma AB Announces National Approval for MOB-015 in Sweden	04/23/04	CI
Moberg Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/23/03	CI
Moberg Pharma AB Announces That Mob-015 has Received National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults	31/23/31	CI
Cipher Pharmaceuticals Partner, Moberg Pharma, Announces Approval for MOB-015 in the European Union	05/23/05	MT
Cipher Pharmaceuticals Brief: Partner, Moberg Pharma Announcing Approval for MOB-015 in the European Union	05/23/05	MT
Moberg Pharma AB Announces Approval for Mob-015 in the European Union	05/23/05	CI
Moberg Pharma's Antifungal Medicine Backed for Approval in 13 EU Nations; Shares Tank 39%	28/23/28	MT
Moberg Pharma AB Recommends for Approval in EU	28/23/28	CI

Chart Moberg Pharma AB

Duration

Period

More charts

Company Profile

Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.

Sector

Pharmaceuticals

Calendar

30/05/2024 - Redeye Growth Day

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MOBERG PHARMA AB	+69.34%	63.78M
ELI LILLY AND COMPANY	+39.22%	731B
NOVO NORDISK A/S	+32.27%	586B
JOHNSON & JOHNSON	-7.85%	348B
MERCK & CO., INC.	+15.48%	319B
ABBVIE INC.	-0.12%	273B
ASTRAZENECA PLC	+13.57%	235B
ROCHE HOLDING AG	-7.08%	203B
NOVARTIS AG	+7.23%	202B
AMGEN INC.	+2.93%	159B

Other Pharmaceuticals

Moberg Pharma AB

Equities

MOB

SE0020353928

Pharmaceuticals

Peter Wolpert and Fredrik Granström Step-Down from the Board

Latest news about Moberg Pharma AB

Chart Moberg Pharma AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals